New antibody drug aims to block Brain-Attacking autoantibodies

NCT ID NCT07093333

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2a trial tests a drug called ART5803 in 30 adults with anti-NMDAR encephalitis or related psychiatric disease. The drug is a lab-made antibody designed to block harmful autoantibodies from attacking brain receptors. The study focuses on safety and tolerability, with early signs of effectiveness also being measured.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ART5803 (a lab-made antibody that blocks harmful autoantibodies from attacking brain receptors)
What this could lead to
If successful, this could point toward a targeted treatment for anti-NMDAR encephalitis and related psychiatric conditions, potentially reducing symptoms and improving quality of life.
What could go wrong
This is an early Phase 2a study with only 30 participants, so results may not apply to everyone. The drug's safety and effectiveness are still unproven, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ANTIBODY-ASSOCIATED PSYCHIATRIC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.